Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Reactivation of fetal hemoglobin expression by the downregulation of BCL11A is a promising treatment for β-hemoglobinopathies. A detailed understanding of BCL11A-mediated repression of γ-globin gene (HBG1/2) transcription is lacking, as studies to date used perturbations by shRNA or CRISPR-Cas9 gene editing. We leveraged the dTAG PROTAC degradation platform to acutely deplete BCL11A protein in erythroid cells and examined consequences by nascent transcriptomics, proteomics, chromatin accessibility, and histone profiling. Among 31 genes repressed by BCL11A, HBG1/2 and HBZ show the most abundant and progressive changes in transcription and chromatin accessibility upon BCL11A loss. Transcriptional changes at HBG1/2 were detected in <2 h. Robust HBG1/2 reactivation upon acute BCL11A depletion occurred without the loss of promoter 5-methylcytosine (5mC). Using targeted protein degradation, we establish a hierarchy of gene reactivation at BCL11A targets, in which nascent transcription is followed by increased chromatin accessibility, and both are uncoupled from promoter DNA methylation at the HBG1/2 loci.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9391307PMC
http://dx.doi.org/10.1016/j.chembiol.2022.06.007DOI Listing

Publication Analysis

Top Keywords

bcl11a protein
8
protein erythroid
8
erythroid cells
8
chromatin accessibility
8
bcl11a
5
temporal resolution
4
resolution gene
4
gene derepression
4
derepression proteome
4
proteome changes
4

Similar Publications

CRISPR/Cas9 genome editing has emerged as a promising treatment for genetic diseases like β-thalassemia. Editing γ-globin promoters to disrupt ZBTB7A/LRF or BCL11A binding sites has shown potential for reactivating fetal hemoglobin and treating sickle cell disease. However, its application to β-thalassemia/HbE disease remains unclear.

View Article and Find Full Text PDF

Backgound: Induction of fetal hemoglobin (HbF; α2γ2) production can alleviate the clinical severity of sickle cell disease (SCD) and β-thalassemia. SNPs (e.g.

View Article and Find Full Text PDF

Background: While an increase in fetal hemoglobin (HbF) has no consequences in healthy adults, clinical benefits can be promoted in sickle cell disease (SCD) and β-thalassemia patients. Single-nucleotide polymorphisms (SNPs) in three genomic regions: the gene cluster, the gene, and the () intergenic region, have been associated with HbF regulation. Therefore, the present study aimed to examine the potential association of SNPs in (rs11886868 and rs1427407), (rs66650371 and rs4895441), (rs7482144), and (rs7924684) with HbF levels in an adult population sample from São Tomé e Príncipe (Central Africa).

View Article and Find Full Text PDF

The transcription factor Bcl11a is essential for B-1a cell maintenance during aging.

Proc Natl Acad Sci U S A

July 2025

Department of Hematology, Tongji Hospital, Frontier Science Center for Stem Cell Research, School of Life Sciences and Technology, Tongji University, Shanghai 200092, China.

B-1a cells, a self-renewing B cell subset essential for innate immunity, produce natural IgM antibodies that defend against pathogens, yet mechanisms sustaining their maintenance during aging remain unclear. We report that aging B-1a cells exhibit hallmarks of decline, including DNA damage, apoptosis, and reduced proliferation, with striking sex-specific disparities: aged females retain higher B-1a cell numbers than males, correlating with enhanced glycolysis and chromatin accessibility. Motif analysis of accessible regions identified the transcription factor Bcl11a, which shows elevated chromatin accessibility and expression in aged female B-1a cells but declines in males.

View Article and Find Full Text PDF

Testicular orphan receptors TR2 and TR4 serve as central regulators of erythropoiesis, orchestrating the entire continuum of erythroid progenitor cell proliferation, differentiation, and maturation. As core components of the direct repeat erythroid determinant (DRED) complex, they activate erythroid-specific transcriptional programs to dynamically control the spatiotemporal expression of globin genes. These nuclear receptors not only engage in functional interactions with key erythroid transcription factors GATA1 and KLF1 to coregulate erythroid differentiation and maturation but also recruit epigenetic modifier complexes such as DNMT1 and LSD1 to modulate chromatin states dynamically.

View Article and Find Full Text PDF